Abstract: A transmucosal psychoactive alkaloid composition including a psychoactive alkaloid extract or synthetic psychoactive alkaloid. The alkaloids in the extract are predominantly dephosphorylated rather than phosphorylated. The transmucosal psychoactive alkaloid composition also includes a mucoadhesive polymer, a carrier, and optional further excipients. The non-ingestive composition may be taken orally through the mucosa. A process for obtaining an oral transmucosal psychoactive alkaloid composition includes dephosphorylating the alkaloid during extraction, purifying the extracted alkaloid and standardizing to a specific concentration by adding measured quantities of excipients.
Type:
Grant
Filed:
August 26, 2023
Date of Patent:
April 16, 2024
Assignee:
Psilo Scientific Ltd.
Inventors:
Ryan Moss, Benjamin Lightburn, Lisa Ranken
Abstract: As a technique for proliferating neural crest cells without reducing differentiation capacity, provided is a method for producing neural crest cells, comprising the steps of: (1) obtaining neural crest cells; and (2) suspension-culturing the neural crest cells in a medium comprising a GSK3? inhibitor and a basic fibroblast growth factor (bFGF), wherein the medium comprises the GSK3? inhibitor with a concentration that exhibits an effect equivalent to that exhibited by CHIR99021 with a concentration of higher than 1 ?M and lower than 5 ?M.
Type:
Grant
Filed:
November 29, 2018
Date of Patent:
April 16, 2024
Assignees:
Kyoto University, Takeda Pharmaceutical Company Limited
Abstract: Disclosed are means, methods, and therapeutic compositions for prevention of memory loss during situations of neuroinflammation. In one embodiment the invention teaches administration of the therapeutic combination of ingredients comprising of pterostilbene, Nigella sativa, sulforaphane, and epigallocatechin-3-gallate (EGCG) to a mammal suffering from inflammation in order to preserver memory function.
Abstract: An acellular, anion-depleted platelet-derived peptide-rich composition comprising proteins, polypeptides and peptides <10 kDa in size, wherein the composition has anti-microbial and/or anti-inflammatory activity is disclosed. The composition can be substantially free of non-active and immunogenic factors. The composition can have a platelet-to-bacteria ratio ?1000:1. The composition can comprise plasma at a range of ?10% to ?50% plasma, optionally about 10% plasma. Methods of using the composition are also disclosed.
Type:
Grant
Filed:
September 30, 2020
Date of Patent:
April 9, 2024
Assignees:
North Carolina State University, The Trustees of the University of Pennsylvania
Inventors:
Jessica M. Gilbertie, Lauren V. Schnabel, Thomas P. Schaer
Abstract: The invention provides an animal chew toy comprising a dental care composition, wherein the dental care composition comprises at least one peroxidase and at least one oxidase.
Abstract: Provided is a composition for preventing, alleviating or treating dry eye syndrome, containing an Aucuba japonica extract as an active ingredient. The composition containing an Aucuba japonica extract can be effectively used in the prevention, alleviation or treatment of dry eye syndrome.
Type:
Grant
Filed:
October 30, 2018
Date of Patent:
March 26, 2024
Assignee:
INDUSTRIAL COOPERATION FOUNDATION CHONBUK NATIONAL UNIVERSITY
Abstract: A biologically active food additive for normalizing the function of the thyroid gland comprises roots or rhizome or the above-ground part of white cinquefoil, or a mixture thereof, purple echinacca and laminaria, with the following ratio of components in mass %: 10-75 of white cinquefoil, 10-50 of purple echinacea and 10-80 of laminaria. The technical result of the invention is the showing of increased efficacy in treating thyroid gland disorders and enhancing the body's immune status, with no side of effects.
Type:
Grant
Filed:
February 13, 2017
Date of Patent:
March 19, 2024
Assignee:
Parapharm LLC
Inventors:
Vyacheslav N Trifonov, Yulia A. Elistratova, Konstantin G. Elistratov, Natalia V. Kurus'
Abstract: A method of removing a floatation liquid from between a microscope slide and a paraffin embedded biological specimen including position the microscope slide with the paraffin embedded biological specimen floated thereon onto a slide support element. The slide support element is rotated to cause the microscope slide and the paraffin embedded biological specimen to move in a way that causes the floatation liquid disposed between the microscope slide and the paraffin embedded biological specimen to be removed from between the microscope slide and the paraffin embedded biological specimen.
Abstract: A preparation method of non-ester tea polyphenols rich in EGC. Includes leaching wall-broken crushed tea leaves using endogenous hydrolytic enzymes contained in the tea leaves; refining the leached solution after filtration and concentration and purifying it by mobile leaching-water washing; concentrating and drying the purified product to obtain a non-ester tea polyphenols product rich in EGC, wherein the content of tea polyphenols is 90-99.5%, the content of EGC is greater than 80%, and the content of ester catechins EGCG+ECG is less than 10%.
Abstract: The present disclosure relates to compositions and methods for helping to manage the lingering symptoms and effects of COVID-19 after recovery. Specifically, the present disclosure relates to sustained release dietary and nutritional supplement compositions and methods to provide ongoing support and symptom management for individuals exposed to SARS-CoV-2 who contacted COVID-19 and later recovered but continue to experience after-effects or lingering symptoms. Specifically, the composition is based on a sustained release ashwagandha extract, alone in a therapeutically effective amount, or in combination with other ingredients.
Abstract: Compositions, methods, and kits for cleansing, moisturizing, soothing, cooling, such as those, for example, that may be used to cleanse, moisturize, soothe, and cool the body or portions thereof.
Type:
Grant
Filed:
April 1, 2022
Date of Patent:
February 20, 2024
Inventors:
Brandon Joseph Karam, Jessica Karam Oley
Abstract: An herbal composition includes a plurality of herbal components designed to work harmoniously together to alleviate pain and reduce inflammation of the oral mucosa. Such pain and inflammation may be associated with, for example, recurrent aphthous stomatitis. The formulation can include ginger, cayenne, cloves, cinnamon, turmeric, and annatto. The herbal composition may be formulated as a candy or gum, for example, to provide effective delivery to the oral mucosa.
Abstract: A composition includes Commiphora mukul extract, Camellia sinensis extract, and Trigonella foenum-graecum extract. The composition may further include Allium sativum extract, Zingiber officinale extract, and Cinnamomum verum extract. The composition may include Commiphora mukul extract at about 24%-36% by weight of the total composition, the Allium sativum extract at about 20%-30% by weight of the total composition, the Camellia sinensis extract at about 12%-18% by weight of the total composition, the Trigonella foenum-graecum extract at about 12%-18% by weight of the total composition, the Zingiber officinale extract at about 8%-12% by weight of the total composition, and the Cinnamomum verum extract at about 4%-6% by weight of the total composition. The disclosure further provides methods of treating hyperlipidemia using the disclosed compositions.
Abstract: A composition for decreasing proliferation of cancer cells undergoing hyperthermia therapy is described. Such compositions can include a combination of selenium and fish oil. The respective quantities of selenium and fish oil are provided in amounts effective to synergistically increase the sensitivity of the cancer cells to temperatures in excess of 37° C.
Abstract: Peptides that specifically bind erythrocytes are described. These are provided as peptidic ligands having sequences that specifically bind, or as antibodies or fragments thereof that provide specific binding, to erythrocytes. The peptides may be prepared as molecular fusions with therapeutic agents, tolerizing antigens, or targeting peptides. Immunotolerance may be created by use of the fusions and choice of an antigen on a substance for which tolerance is desired. Fusions with targeting peptides direct the fusions to the target, for instance a tumor, where the erythrocyte-binding ligands reduce or entirely eliminate blood flow to the tumor by recruiting erythrocytes to the target.
Type:
Grant
Filed:
January 7, 2021
Date of Patent:
January 30, 2024
Assignee:
École Polytechnique Fédérale de Lausanne (EPFL)
Inventors:
Jeffrey A. Hubbell, Stephan Kontos, Karen Y. Dane
Abstract: Embodiments of the invention include a system having a plant stem cell product and a delivery device configured to deliver an effective amount of the plant stem cell product to the oral cavity or nasopharynx. In some embodiments, the delivery device may include an aerosolizing device, an adherent dressing, a tooth-adherent flexible strip, a treatment tray, a viscous adherent carrier, a brush, a paste, a flosser, a dissolving oral strip, a gum, a chew, a smoking material, a nasal packing, or a lozenge. The plant stem cell products may include encapsulated extracts of plant stem cells, such as food species stem cells, spice or other seasoning stem cells, or medicinal plant stem cells.
Abstract: A composition and method for reversing or preventing age-related metabolic and tissue degenerative changes in individuals. The method includes administering, orally, an effective amount of a first composition having methioninase enzyme. The method further includes administering, by a route other than the oral route, such as a parenteral route, an effective amount of a second composition having methioninase enzyme. The method further includes the steps of orally and/or parentally administering pyridoxal-L-phosphate.
Abstract: There is provided a vegetable-based lipid composition comprising very high levels of DHA, together with at least one other long-chain polyunsaturated fatty acid (typically as fatty acid esters). The composition typically contains low levels of EPA and palmitic acid. The composition is obtainable from a single source by conventional processing methods, and has improved stability properties.
Abstract: The present invention is directed to a therapeutic composition including an active therapeutic ingredient combined with a liquid or solution based carbonated beverage. The invention as described details the use or administration of the therapeutic composition so as to treat a variety of ailments. The present invention is also directed to a method of administering the therapeutic composition to an individual for the purposes of alleviating an ailment. In a further arrangement, the therapeutic composition is provided to a user as a pre-packaged volume containing a single effective dose of the therapeutic agent.
Abstract: The present invention relates to a process for producing an extract powder from a fruit material of e.g. berry fruits, wherein anthocyanins are enriched from the fruit material, and to the product obtainable by the process. In the process according to the invention, anthocyanins are enriched via a cation exchanger. By eluting the anthocyanins from the cation exchanger by means of L-arginine, the process has the advantage that no salt needs to be purified from the eluate to produce an extract powder suitable for use as a dietary supplement.
Type:
Grant
Filed:
November 15, 2021
Date of Patent:
January 9, 2024
Assignee:
Deutsches Institut für Lebensmitteltechnik e.V.